Journal
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY
Volume 34, Issue 2, Pages 187-194Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jvir.2022.10.039
Keywords
-
Ask authors/readers for more resources
This study compared the clinical outcomes of TIPS creation and PVS in patients with noncirrhotic CTPV. The results showed that PVS had lower stent occlusion rate, lower risk of variceal rebleeding, and fewer adverse events compared to TIPS, indicating that PVS may be a preferable alternative for the treatment of noncirrhotic CTPV.
Purpose: To compare the clinical outcomes of transjugular intrahepatic portosystemic shunt (TIPS) creation versus portal vein stent placement (PVS) in patients with noncirrhotic cavernous transformation of the portal vein (CTPV).Materials and Methods: In this retrospective study, clinical data from patients with noncirrhotic CTPV who underwent TIPS creation or PVS were compared. A total of 54 patients (mean age, 43.8 years & PLUSMN; 15.8; 31 men and 23 women) were included from January 2013 to January 2021; 29 patients underwent TIPS creation, and 25 patients underwent PVS. Stent occlusion, variceal rebleeding, survival, and postprocedural complications were compared between the 2 groups. Results: The mean follow-up time was 40.2 months & PLUSMN; 26.2 in the TIPS group and 35.3 months & PLUSMN; 21.1 in the PVS group. The stent occlusion rate in the PVS group (16%, 4 of 25) was significantly lower than that in the TIPS group (41.4%, 12 of 29) during the follow-up (P = .042). The cumulative variceal rebleeding rates in the TIPS group were significantly higher than those in the PVS group (28% vs 4%; P = .027). The procedural success rate was 69% in the TIPS group and 86% in the PVS group (P = .156). There was a higher number of severe adverse events after TIPS than after PVS (0% vs 24%; P = .012). Conclusions: Portal vein recanalization with PVS may be a preferable alternative to TIPS creation in the treatment of noncirrhotic CTPV because of higher stent patency rates, lower risk of variceal rebleeding, and fewer adverse events.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available